Improvement of cardiovascular risk factors in patients with type 2 diabetes after long‐term continuous subcutaneous insulin infusion

2008 ◽  
Vol 24 (5) ◽  
pp. 384-391 ◽  
Author(s):  
Yun‐Hee Noh ◽  
Se‐Myung Lee ◽  
Eun‐Ju Kim ◽  
Do‐Young Kim ◽  
Hyunil Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Subcutaneous Insulin

scholarly journals Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors

2018 ◽  
Vol 123 (3) ◽  
pp. 519-529 ◽  
Author(s):  
Geoffrey Hackett ◽  
Nigel Cole ◽  
Akhilesh Mulay ◽  
Richard C. Strange ◽  
Sudarshan Ramachandran
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Testosterone Therapy

scholarly journals An Audit of Clinical Practice in a Single Centre in Kuwait: Management of Children on Continuous Subcutaneous Insulin Infusion and Cardiovascular Risk Factors Screening

2017 ◽  
Vol 11 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Dina Omar ◽  
Hala Alsanae ◽  
Mona Al Khawari ◽  
Majedah Abdulrasoul ◽  
Zahraa Rahme ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Practice ◽  
Cardiovascular Risk ◽  
Children And Adolescents ◽  
Cardiovascular Risk Factors ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Subcutaneous Insulin ◽  
Single Centre ◽  
Acute Complications

Objectives: To audit the current clinical practice of continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetes mellitus (T1D) in children and adolescents attending a single centre in Kuwait. Methods: A one year retrospective audit was performed in children and adolescents with T1D on CSII, who attended the paediatric diabetes clinic, Dasman Diabetes Institute during 2012. The primary outcome measure was glycaemic control as evidenced by glycated haemoglobin (HbA1c) level and the secondary outcome measures were the frequency of monitoring of the risk for microvascular complications and occurrence of acute complications and adverse events. Results: 58 children and adolescents (mean age ± SD: 12.6 ± 4.1 years) were included. Mean HbA1c at baseline was 8.8% (72.7 mmol/mol) and 8.9% (73.8 mmol/mol) at the end of a 12 months observation period. Children with poor control (HbA1c >9.5% (80 mmol/mol) had a significant 1.4% reduction in HbA1c compared with the overall reduction of 0.1% (p=0.7). Rate of screening for cardiovascular risk factors and for long term complications were well documented. However, there was underreporting of acute complications such as severe hypoglycaemia and diabetic ketoacidosis. Only 1.7% of patients discontinued the pump. Conclusion: There was no significant change in HbA1c values at the end of 12 months follow up. However, HbA1c values in poorly controlled children improved. CSII requires care by skilled health professionals as well as education and selection of motivated parents and children.

Sign in / Sign up

Export Citation Format

Share Document